Stock Information
Alkermes Plc (ALKS)
Ticker Symbol: ALKS
Exchange: NASDAQ
Sector: Biotechnology
Market Cap: $5,911.07 mil
Piotroski score: 1
PE Ratio: 57.3303
EPS (TTM): 0.8993
Revenue (TTM): $9.40 M
Dividend Yield: N/A%
ROE: 8.82%
Latest News
-
BofA cuts ratings on four biopharma stocks over valuation and catalyst concerns
Mon, Jun 29, 2026 4:01 PM
-
Alkermes Faces Risk on Orexin-Related Value From Upcoming Updates, BofA Says
Mon, Jun 29, 2026 3:14 PM
-
Adobe downgraded, Roblox upgraded: Wall Street's top analyst calls
Mon, Jun 29, 2026 1:44 PM
-
Here Are Monday’s Best Wall Street Analyst Research Calls: Adobe, Applovin, Casey’s General Stores, CrowdStrike, Honeywell Aerospace, Salesforce, Synaptics, Terawulf, and More
Mon, Jun 29, 2026 12:21 PM
-
Wells Fargo Maintains Overweight on Alkermes, Raises Price Target to $65
Mon, Jun 29, 2026 9:33 AM
-
This Liquidia Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday
Mon, Jun 29, 2026 8:49 AM
-
B of A Securities Downgrades Alkermes to Underperform, Announces $38 Price Target
Mon, Jun 29, 2026 8:01 AM
-
Alkermes’ incoming CEO has a plan to outplay Lilly and Takeda
Fri, Jun 26, 2026 9:46 AM
-
Jazz Pharmaceuticals: Why It's Time To Cash Out (Rating Downgrade)
Fri, Jun 26, 2026 9:22 AM
-
Needham Maintains Buy on Alkermes, Raises Price Target to $61
Wed, Jun 24, 2026 7:10 AM
Key Financials
Financial data not available
